Literature DB >> 29373110

Gorlin Syndrome.

I Palacios-Álvarez1, R González-Sarmiento2, E Fernández-López3.   

Abstract

Gorlin syndrome is a rare autosomal dominant disease caused by mutations in the sonic hedgehog signaling pathway. Of particular importance is the PTCH1 gene. The disease is characterized by the development of multiple basal cell carcinomas at young ages. These tumors may present with other skin manifestations such as palmoplantar pits and with extracutaneous manifestations such as odontogenic keratocysts and medulloblastoma. Although the dermatologist may be key for recognizing clinical suspicion of the syndrome, a multidisciplinary team is usually necessary for diagnosis, treatment, and follow-up. Skin treatment may be complicated due to the large number of basal cell carcinomas and the extent of involvement. In recent years, new drugs that inhibit targets in the sonic hedgehog pathway have been developed. Although these agents appear promising options for patients with Gorlin syndrome, their efficacy is limited by adverse effects and the development of resistance.
Copyright © 2017 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Basal cell carcinoma; Basal cell nevus syndrome; Carcinoma basocelular; Gorlin syndrome; PTCH1 protein; Proteína PTCH1; Síndrome de Gorlin; Síndrome del nevo basocelular; Tratamiento; Treatment

Mesh:

Year:  2018        PMID: 29373110     DOI: 10.1016/j.ad.2017.07.018

Source DB:  PubMed          Journal:  Actas Dermosifiliogr (Engl Ed)        ISSN: 2173-5778


  2 in total

1.  Gorlin syndrome - Case report.

Authors:  Tzu Hsien Yeh; Yen-Chang Chen; Yi-Pang Lee; Chun-Pin Chiang
Journal:  J Dent Sci       Date:  2022-05-21       Impact factor: 3.719

2.  Profile of Basal Cell Carcinoma Mutations and Copy Number Alterations - Focus on Gene-Associated Noncoding Variants.

Authors:  Paulina Maria Nawrocka; Paulina Galka-Marciniak; Martyna Olga Urbanek-Trzeciak; Ilamathi M-Thirusenthilarasan; Natalia Szostak; Anna Philips; Laura Susok; Michael Sand; Piotr Kozlowski
Journal:  Front Oncol       Date:  2021-11-25       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.